ClinicalTrials.gg
Not yet recruitingNCT02933229Updated Oct 14, 2016

The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study

A Phase 4 interventional study of biopsy and H. pylori eradication in Helicobacter Pylori, the Operative Link on Gastric Intestinal Metaplasia and Operative Link on Gastric Intestinal Assessment, sponsored by Shandong University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Shandong University · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Metaplasia by Shandong University — 1 open to participants now, 1 under way, none of them phase 3. Metaplasia · Shandong University.

Started
2016
with 4 others
Phase 4
3 of 18
1 open now
Registered
12th of 18
by date

Among the 18 studies in Metaplasia by Shandong University, this one is one of 5 that started in 2016, is one of 3 in phase 4, and was the 12th registered.

Metaplasia

45 studies on the registry are indexed under Metaplasia; 11 are open to participants now.

Browse Metaplasia studies →

Open to participants now

1 of the 18 studies in Metaplasia by Shandong University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 7 Metaplasia studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Metaplasia by Shandong University, or all of them as a file.
02

Study summary

Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies

03

Conditions studied

  • Helicobacter Pylori
  • the Operative Link on Gastric Intestinal Metaplasia
  • Operative Link on Gastric Intestinal Assessment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with H. pylori infection;
  • Aged 18-65 years.

Exclusion criteria

Exclusion Criteria:

  • Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;
  • Conditions unsuitable for performance of gastroscopy, such as coagulopathy, impaired renal function;
  • Pregnancy or breastfeeding;
  • Inability to provide and other situations that could interfere with the examination or therapeutic protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    H. pylori eradication cohort

    H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin. If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.

    Device: biopsy · Drug: H. pylori eradication

Interventions

  • Devicebiopsy

    patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.

  • DrugH. pylori eradication

    H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin. If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.

06

What researchers measure

Primary outcomes

  1. The proportion of more severe inflammation in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status

    Time frame: 15 years

  2. The proportion of more severe atrophy in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status

    Time frame: 15 years

  3. The proportion of more severe IM in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status

    Time frame: 15 years

Secondary outcomes

  1. The proportion of more advanced stages for 15 years after H. pylori eradication by using operative link on gastritis assessment (OLGA) system compared with original status.

    Time frame: 15 years

  2. The proportion of more advanced stages for 15 years after H. pylori eradication by using operative link for gastritis intestinal metaplasia (OLGIM) system compared with original status.

    Time frame: 15 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Oct 2031 and a completion of Oct 2031. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2016
First posted
Oct 14, 2016
Start
Oct 2016
Primary completionEst.
Oct 2031
CompletionEst.
Oct 2031
Last update
Oct 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02933229
Responsible party
Yanqing Li (Vice president of Qilu Hospital, Shandong University) — Principal investigator
First posted
Oct 14, 2016
Start date
Oct 2016
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Oct 14, 2016

Study contacts

Li Yanqing, MD, PhD
Contact
liyanqing@sdu.edu.cn
86-531-82169236
Li Yanqing, MD, PhD
principal investigator · Qilu Hospital of Shandong University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion